Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies

Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.

(2017) N. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of sequential FDG-PET/CT to guide extent of axillay lymph node dissection in breast cancer receiving neoadjuvant chemotherapy.

(2017) B. Keam et al.   JOURNAL OF CLINICAL ONCOLOGY

Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL).

(2017) R. W. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

(2017) B. Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

(2011) L. Lee et al.   ANNALS OF ONCOLOGY

Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management Approach

(2011) Karen Carlson et al.   Clinical Breast Cancer

Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer

(2011) Aaron S. Kesselheim   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma

(2010) Hans-Peter Gerber   BIOCHEMICAL PHARMACOLOGY

MicroRNA expression in maturing murine megakaryocytes

(2010) J. B. Opalinska et al.   BLOOD

Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients

(2010) B L McClune et al.   BONE MARROW TRANSPLANTATION

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases

(2010) Tanzina Haque et al.   JOURNAL OF MEDICAL VIROLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

(2009) M. P. Purdue et al.   BLOOD

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

TRAF1 is involved in the classical NF-κB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells

(2009) Feng Guo et al.   MOLECULAR IMMUNOLOGY

CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells

(2008) Burkhard Hirsch et al.   AMERICAN JOURNAL OF PATHOLOGY

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD

Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas

(2008) K. J. Savage   Hematology-American Society of Hematology Education Program

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2007) Anna Sureda et al.   JOURNAL OF CLINICAL ONCOLOGY